H.C. Wainwright upgraded Kyverna Therapeutics (KYTX) to Buy from Neutral with a $5 price target The company is set to produce three sets of data through mid-2025, with potential opportunity to demonstrate success across three KYV-101 pipeline programs, the analyst tells investors in a research note. Ahead of the three catalysts, the firm thinks the stock’s risk/reward profile attractive, “particularly given a deeply negative enterprise value.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics: Strong Clinical Progress and Regulatory Alignment Support Buy Rating
- Kyverna Therapeutics Reports Q1 2025 Progress and Outlook
- Kyverna Therapeutics: Strategic Advancements and Clinical Progress Drive Buy Rating
- Kyverna Therapeutics reports Q1 EPS ($1.03), consensus ($1.00)
- Kyverna Therapeutics price target lowered to $4 from $6 at H.C. Wainwright